Filing Flows

Filing Flows › Maravai Lifesciences Holdings (MRVI) › Q1 2026

Maravai Lifesciences Holdings (MRVI) Q1 2026 earnings results (first quarter 2026)

10-Q filed May 8, 2026

Maravai Lifesciences Holdings (MRVI) reported revenue of $65.8M for the first quarter 2026 (Q1 2026), +41% from a year earlier and +32% from the quarter before. Operating margin was -3.3%, net loss $6.4M (9.7% of revenue).

Revenue$65.8M
Year over year+41%
Quarter over quarter+32%
Operating margin-3.3%
Net earnings−$6.4M

Maravai Lifesciences Holdings, Q1 2026: revenue $65.8M (+40% year over year), operating margin -3.3%, net loss $6.4M, operating cash flow $8.7M. The chart follows the revenue to costs, profit and cash.

Q1 2026AmountQ/QY/Y
Revenue$65.8M+32%+41%
Operating profit−$2.2M——
Net earnings−$6.4M——
Operating cash flow$8.7M——
Free cash flow$4.2M——

What changed

Revenue was $65.8M in Q1 2026, up 41% year over year and up 32% from the previous quarter. TriLink was the largest line at 72% of revenue. TriLink added $18.7M year over year (up 65%), 99% of the total change.

Gross margin was 51.2%, up 34.7 points from Q1 2025. Operating costs exceeded revenue by $2.2M, an operating margin of -3.3%. Operating expenses fell 37% while revenue rose 41%. The quarter ended with a net loss of $6.4M, narrower than the previous quarter's $63.0M loss. Minority interests bore $2.6M of it: to shareholders the quarter was a loss of $3.7M. Net interest and other expense of $4.4M was the main reason.

Operating cash flow was $8.7M. Non-cash charges added back $11.4M of depreciation and amortization and $6.7M of share-based compensation. Working capital and other items used $3.1M. After purchases of property and equipment ($4.4M), free cash flow as the company reports it was $4.2M.

Questions

What was Maravai Lifesciences Holdings' revenue in the first quarter 2026?

Maravai Lifesciences Holdings (MRVI) reported revenue of $65.8M for the first quarter 2026 (Q1 2026), +41% from a year earlier and +32% from the quarter before.

Was Maravai Lifesciences Holdings profitable in the first quarter 2026?

Operating loss was $2.2M (-3.3% of revenue) and net loss $6.4M.

Open the interactive Sankey →

Source: Maravai Lifesciences Holdings 10-Q on SEC EDGAR.